Deletion of SHP-2 in myeloid cells curbs B16 melanoma growth and boosts tumor concentrations of chemoattractant CXCL9, macrophage-produced IFNγ-induced CXCL9, and CD8+ T cell infiltration into tumors. Here, CXCL9 is linked to neoplasm.